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Abstract
Objective: To provide HIV seroincidence data among men who have sex with men (MSM) in the United States and to
identify predictive factors for seroconversion.
Methods: From 1998–2002, 4684 high-risk MSM, age 18–60 years, participated in a randomized, placebo-controlled HIV
vaccine efficacy trial at 56 U.S. clinical trial sites. Demographics, behavioral data, and HIV status were assessed at baseline
and 6 month intervals. Since no overall vaccine efficacy was detected, data were combined from both trial arms to calculate
HIV incidence based on person-years (py) of follow-up. Predictors of seroconversion, adjusted hazards ratio (aHR), were
evaluated using a Cox proportional hazard model with time-varying covariates.
Results: Overall, HIV incidence was 2.7/100 py and was relatively uniform across study sites and study years. HIV incidence
was highest among young men and men reporting unprotected sex, recreational drug use, and a history of a sexually
transmitted infection. Independent predictors of HIV seroconversion included: age 18–30 years (aHR=2.4; 95% CI 1.4,4.0),
having .10 partners (aHR=2.4; 95% CI 1.7,3.3), having a known HIV-positive male sex partner (aHR=1.6; 95% CI 1.2, 2.0),
unprotected anal intercourse with HIV positive/unknown male partners (aHR=1.7; 95% CI 1.3, 2.3), and amphetamine
(aHR=1.6; 95% CI 1.1, 2.1) and popper (aHR=1.7; 95% CI 1.3, 2.2) use.
Conclusions: HIV seroincidence was high among MSM despite repeated HIV counseling and reported declines in sexual risk
behaviors. Continuing development of new HIV prevention strategies and intensification of existing efforts will be necessary
to reduce the rate of new HIV infections, especially among young men.
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Introduction
Currently human immunodeficiency virus (HIV) infects
,48,000 persons in the United States annually, and 57% of
HIV/AIDS cases are reported among men who have sex with
men (MSM) [1,2]. Although rates of HIV infection among MSM
in the United States declined in the late 1980s and early 1990s,
subsequent data indicated increases in HIV infections, sexually
transmitted infections (STIs), and unsafe sexual practices among
this population [3–15]. In general, estimates of HIV seroincidence
among U.S. MSM are largely based on (1) small regional or local
cohort studies which follow individuals for short time periods, (2)
national HIV surveillance data from selected locations, and (3)
cross-sectional studies or samples which use the BED HIV-1 assay
within the serologic testing algorithm for recent HIV seroconver-
sion (STARHS) to estimate HIV seroincidence. Large national
MSM cohort studies remain the gold standard for HIV incidence
estimates and can be utilized to provide data for a variety of age
groups and geographic regions as well as valuable information on
trends and risk factors for infection.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34972From 1998–2002, a large multi-site phase III HIV vaccine
efficacy trial was conducted among 5108 high-risk HIV-1 negative
MSM and 309 heterosexual women in North America and the
Netherlands; U.S. MSM accounted for over 90% of study
participants. Although the vaccine did not demonstrate efficacy
[16,17], enrollment and retention of high-risk participants were
excellent [17,18]. Thus, epidemiologic and behavioral data from
this 36-month trial are useful for characterizing national trends in
HIV incidence and identifying risk factors for HIV infection
among U.S. MSM.
Methods
Study population
From June 1998 through October 1999, VaxGen, Inc.
(Brisbane, CA) enrolled 4697 HIV-seronegative MSM into a 36-
month, randomized (2:1 vaccine:placebo), double-blind, placebo-
controlled phase III HIV-1 vaccine efficacy trial at 56 clinical trial
sites in 47 cities in the United States. Enrolled MSM were healthy,
18–60 years of age, and reported having anal sex with $1 HIV
positive or unknown serostatus male partner during the past year.
Men in a monogamous relationship for $1 year with a HIV
seronegative male partner or who reported injection drug use
(IDU) in the preceding three years were excluded from enrollment.
Recruitment strategies included advertising, outreach, and refer-
rals from other cohort studies, from HIV-infected partners, and
current trial participants.
HIV counseling and testing was conducted at enrollment,
semiannually, and at participant request. Participants diagnosed
with HIV infection during the trial were referred for medical care
and social services. Nucleic acid testing (NAT) detected 13 HIV
infections among MSM at enrollment; these men were discontin-
ued from the trial resulting in 4684 MSM eligible for subsequent
incidence analyses. Details of the trial baseline methods, study
procedures, and efficacy results have been published elsewhere
[17,18].
Ethics Statement
The vaccine study protocol was approved by the institutional
review boards (IRB) of Saint Louis University, John Hopkins
University School of Medicine, Fenway Community Health
Center, Philadelphia Fight, AIDS Research Alliance, Louisiana
State University Medical Center, University of California, Irvine,
University of California, San Francisco, University of Washington,
Hennepin County Medical Center, Mount Sinai Medical Center,
the University of New Mexico, the University Medical Center of
Southern Nevada, Abbot Northwestern Hospital, New York Blood
Center, New York Medical Center, Howard Brown Health
Center, Ohio State University, the University of Texas, Galveston,
the University of California, Davis, Community AIDS Resource,
Inc., University of Hawaii, the AIDS Research Consortium of
Atlanta, Erie County Medical Center, Santa Clara County Public
Health Department, Albany Medical College, New Jersey
Community Research Initiative, Duval County Health Depart-
ment, University Hospitals of Cleveland, University of Alabama at
Birmingham, Community Hospitals Indianapolis, Wisconsin
AIDS Research Consortium, University of Pittsburgh, Miriam
Hospital, Nalle Clinic, and Memorial Hospital of Rhode Island,
the Colorado Multiple IRB, the Western IRB, and the IRB of the
Centers for Disease Control and Prevention (CDC). All partici-
pants provided written informed consent for trial participation.
Data collection
At enrollment, a standardized interviewer-administered ques-
tionnaire was used to collect information on demographics,
medical history, and reasons for trial participation. Data on STI
diagnoses, concomitant medications, and sexual risk behaviors
(i.e., unprotected receptive or insertive anal intercourse [UAI])
with partners by HIV-serostatus (negative, positive, and unknown)
in the previous 6 months were collected at enrollment and 6
month intervals. Participants were also asked if they had injected
drugs during the past six months, or if they had used marijuana/
hash, poppers, crack or cocaine, amphetamines (e.g., crystal or
speed), tranquilizers/sedatives (e.g., valium, Xanax, Klonopin,
barbiturates, Quaaludes), hallucinogens (e.g., PCP, Special K,
angel dust, acid, LSD, mushrooms, ecstasy), heroin, or drugs to
enhance sexual performance (e.g., Viagra, Yohimbine). Two
questionnaire items designed to assess beliefs about HIV vaccine
trial participation that may increase HIV risk behavior, such as
perceiving a high degree of protection against HIV if the vaccine
was shown to be efficacious and perceiving vaccine treatment
assignment were asked at enrollment (the first item) and at 12, 24,
and 36 months (the second item).
Laboratory Testing
Specimens were tested using an enzyme immunoassay (EIA) at a
central laboratory; EIA reactive specimens were confirmed by
Western Blot. If HIV seropositivity was detected, a specimen
available at the time of the last negative EIA was tested by NAT
(Procleix HIV-1 Discriminatory Assay, Gen-Probe, Inc., San
Diego, CA) to determine viremia at an earlier visit.
Statistical analysis
Incidence density was calculated by baseline characteristics
based on person-years (py) of follow-up for HIV seronegative
MSM who received at least one additional HIV test during the
trial. The Breslow-Day test was used to assess heterogeneity in
HIV incidence over time. Date of HIV infection was defined as the
midpoint between the last negative and the first positive EIA or
date of first positive NAT. A Cox proportional hazards model
identified baseline variables predictive of loss-to-follow up.
Baseline variables were evaluated to examine differences in
reported risk behaviors between young (18–30 years of age) and
older MSM using the Mantel-Haenszel [chi]
2 test. Potentially
predictive (p,.20) characteristics for HIV seroconversion identi-
fied in univariate Cox proportional hazards models with time-
varying covariates updated every 6 months and forced inclusion of
treatment arm assignment were assessed in a multivariate Cox
proportional hazards model including partner serostatus, numbers
of sexual partners, UAI, recreational drug use, age, and STI.
Analyses were conducted using SAS (version 8.0; SAS Institute,
Cary, NC).
Results
Participants
From June 1998 through October 1999, 4684 HIV-1
seronegative male trial participants enrolled at 56 clinical trial
sites in 47 U.S. cities, encompassing 27 states, Washington, DC,
and Puerto Rico. The median number of MSM enrolled per site
was 75 (range, 5–303). Retention at 6, 12, 18, 24, 30, and 36
months was 96%, 92%, 89%, 87%, 85% and 82%, respectively.
Loss-to-follow-up was independently associated with the following
baseline characteristics: age 18–30 years (p,.0001), African
American (p,.01) and Hispanic (p,.01) race, tranquilizer
(p,.0001) and crack (p,.01) use. Retention was associated with
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use and completing college (p,.0001).
The baseline demographic and sexual risk behavioral charac-
teristics of the U.S. MSM are presented in Table 1. The median
age was 35 years, range 18–62; 25% were 18–30 years of age. Men
were predominantly of white race/ethnicity, and most reported
attaining at least one college degree. The majority of MSM were
enrolled at clinical sites in the southern or western United States.
The median number of male sex partners in the 6 months before
enrollment was 5 (range 0–960 partners); 32% reported having
$10 male partners. In the previous six months, 10% reported
having a STI, and over half reported UAI. IDU was minimal
Table 1. US MSM HIV seroincidence (per 100 person-years) by participant demographic and behavioral characteristics at
enrollment (n=4684).
Characteristic No. (%) N=4684 No. SC N=338 HIV Incidence/100 py (95% CI)
Age category (years)
18–30 1153 (25) 117 3.7 (3.0, 4.5)
31–40 1917 (41) 144 3.0 (2.6, 3.5)
41–50 1192 (25) 61 2.0 (1.6, 2.6)
.51 422 (19) 16 1.6 (0.9, 2.5)
Race/Ethnicity
White 4012 (86) 287 2.7 (2.4, 3.1)
Hispanic 319 (7) 22 2.8 (1.8, 4.3)
African American 173 (4) 10 2.3 (1.1, 4.4)
Asian 72 (2) 6 3.1 (1.2. 6.8)
Other 108 (2) 13 4.7 (2.5, 8.2)
Education level
,High school 55 (1) 2 1.7 (.28, 5.5)
High school 1678 (36) 132 3.2 (2.7, 3.9)
College 2950 (63) 204 2.6 (2.3, 3.0)
Geographic region of enrollment
Midwest 912 (19) 56 2.4 (1.8, 3.1)
Northeast 873 (19) 60 2.6 (2.0, 3.4)
South 1490 (32) 105 2.9 (2.4, 3.5)
West 1409 (30) 116 3.2 (2.6, 3.8)
Sexual risk behavior in previous 6 months
Having .1 female sex partner 221 (5) 10 1.9 (0.9, 3.5)
Having .1 HIV-infected male partner 2064 (44) 193 3.5 (3.0, 4.1)
Any UAI 2713 (58) 254 3.6 (3.2, 4.1)
Any receptive UAI 1727 (37) 195 4.4 (3.8, 5.0)
Any insertive UAI 2212 (47) 202 3.9 (3.3, 4.5)
UAI with positive/unknown serostatus partner 1838 (39) 189 3.9 (3.4, 4.6)
Receptive UAI with positive/unknown serostatus partner 944(20) 123 4.9 (4.0, 5.8)
Insertive UAI with positive/unknown serostatus partner 1447 (31) 156 4.1 (3.5, 4.8)
History of STI 450 (10) 31 3.8 (2.6, 4.4)
History of recreational drug/substance use in previous
6 months
Injection drug use 11 (.23) 1 2.8 (2.5, 3.1)
Amphetamines 417 (9) 62 5.0 (3.8, 6.4)
Crack 92 (2) 13 5.2 (2.7, 8.8)
Cocaine 575 (12) 58 4.0 (3.1, 5.2)
Poppers 1458 (31) 168 4.4 (3.8, 5.2)
Tranquilizers 629 (13) 56 3.6 (2.7, 4.6)
Sexual performance enhancing drugs 590 (13) 59 3.7 (2.8, 4.8)
Hallucinogens 603 (13) 70 4.6 (3.6, 5.9)
Alcohol 4067 (87) 617 2.8 (2.5, 3.1)
NOTE: Not all columns add up to 4684 due to non-response. SC, seroconverters; UAI, unprotected anal intercourse.
doi:10.1371/journal.pone.0034972.t001
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use (e.g., amphetamines, tranquilizers, poppers, cocaine, halluci-
nogens, and sexual performance enhancing drugs), and 87%
reported alcohol use.
Young men (#30 years of age) were less likely than older men to
report a male HIV-infected partner at enrollment, but were more
likely to report any receptive UAI 41% vs. 35% (p=,.001). They
were also less likely than older men to report use of poppers or
sexual performance enhancing drugs, but more likely to report
using marijuana, amphetamines, cocaine, and hallucinogens.
Furthermore, over the course of the study, amphetamine use
significantly increased among young men (from 11% at baseline to
16% at 36 months; p=,.01). The use of other recreational drugs
did not differ by age or time.
HIV Incidence
A total of 338 HIV infections were detected among the 4684
MSM during the trial. Fifty-one sites reported $1 case of HIV
infection. Participants who became infected with HIV were
predominantly white (85%); 60% reported a college degree. The
median age at the time of infection was 36 years (range, 20–62
years), and the median time to infection after study enrollment was
16 months (range, .6–35 months).
Overall, HIV seroincidence was 2.7/100 py (95% CI, 2.5, 3.0)
and was relatively consistent across study year (1998–99, 78 cases,
2.5/100 py, 2000, 137 cases, 3.2/100 py, 2001, 101 cases, 2.7/100
py, and 2002, 22 cases, 1.8/100 py [p=.05]). Incidence did not
vary by geographic region or race/ethnicity (Table 1), but was
substantially higher among young MSM (3.7/100 py; 95% CI 3.0,
4.5). Twenty-three cities had HIV seroincidence rates above 2.7/
100 py; twelve cities exceeded 3.5/100 py (Figure 1). Although,
HIV incidence was expectedly high among MSM from New York
City and Denver, it was also high among MSM from Atlanta,
Houston, Jacksonville, and Phoenix. HIV seroincidence was
highest among MSM who reported receptive UAI with HIV
positive or unknown partners at baseline, followed closely by any
receptive UAI, and then any UAI with HIV positive or unknown
male partners. Elevated HIV seroincidence rates were noted
among men who reported baseline recreational drug use,
especially amphetamines (5.0/100 py; 95% CI 3.8, 6.4) and crack
(5.2/100 py; 95% CI 2.7, 8.8).
Factors predictive of HIV seroconversion
In univariate analysis, young men, men who reported a STI, or
recreational drug use were more likely to seroconvert (Table 2).
Variables, such as education level, geographic region, and race/
ethnicity, and treatment arm assignment (HR=1.01; 95% CI
0.78, 1.31) were not significant. Sexual risk behaviors predictive of
HIV infection included: multiple male sex partners, reporting $1
HIV positive male sex partners and reporting UAI with HIV
positive or unknown male partners. Perceived vaccine efficacy and
perceived treatment assignment were not predictive of HIV
seroconversion, p=.47, and p=.62, respectively.
In the multivariate time-varying model, significant predictors of
HIV seroconversion included younger age, reporting greater
numbers of male sex partners, having at least one HIV-infected
male sex partner, UAI with HIV positive or unknown male
partners during the preceding 6 months, and amphetamine and
popper use (Table 2). The following variables were included in the
model but were not significant: date of study entry, race, education
level, geographic region, and treatment arm assignment
(aHR=1.04; 95% CI 0.80, 1.36).
Discussion
This analysis of data from a large HIV vaccine efficacy trial in
U.S. MSM provides important information about the national
HIV epidemic. Although a largely white population, over 70% of
participants were enrolled from cities lacking substantial epidemi-
ologic information derived from MSM HIV seroincidence cohorts
[19–23]. It is noteworthy how consistent MSM HIV seroincidence
was across U.S. cities.
From 1998–2002, HIV seroincidence was 2.7/100 py among
this U.S. MSM cohort. It remained relatively constant over each
year of observation despite intensive ongoing HIV counseling and
testing and reported decreases in HIV sexual risk behaviors [24].
Figure 1. HIV incidence among MSM study participants in the United States, by city, 1998–2002*.
doi:10.1371/journal.pone.0034972.g001
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race/ethnicity, education level, and calendar year, but substan-
tially higher incidence was observed among younger men and men
who reported risky sexual behaviors, recreational drug use, or a
STI history at baseline. Many of these items were confirmed in the
time varying multivariate model which indicated that younger age,
having a positive male partner, UAI with an HIV-infected or
unknown serostatus male partner, multiple male sex partners, and
amphetamine and popper use were all independently predictive of
HIV infection.
Since this trial excluded men who reported current IDU, few
reported its use, and it was not incorporated into the multivariate
model. However, non-injection recreational drug use was
extremely high. Over 60% of MSM reported recreational drug
use at enrollment, and high HIV seroincidence was seen among
those MSM. Amphetamine and popper use were significantly
linked to higher risks of seroconversion. Although, this study did
not collect data on circumstances of drug use, other studies have
demonstrated sexual situation-specific use of recreational drugs
among MSM [25–29]. The popularity of these drugs is attributed
to their reported abilities to facilitate access to certain types of
sexual partners, specific types of sexual exchange, and to improve
sexual performance [29,30]. Amphetamines, methamphetamine
in particular, have been associated with unprotected intercourse
among both HIV negative and HIV positive MSM [26,27,31–36],
condom failure [37] and HIV infection [23,25,28,38]. Given these
findings, it was concerning that amphetamine use increased over
the course of the trial, suggesting concurrent and continued
expansion in MSM populations outside the trial and subsequent
increases in HIV incidence, especially among young users.
Seroincidence among young men was much higher compared
to older MSM, and younger age was a significant predictor of HIV
seroconversion. These data confirm results from other studies that
young MSM are at greater risk for HIV seroconversion [19,39–
41] perhaps due to riskier sexual activities [11,19,42], partner
choice [43,44], internet-facilitated higher risk sexual encounters
[45–49] and psychosocial attitudes [42,50]. Without targeted
Table 2. Risk factors for HIV infection among MSM in univariate and multivariate analyses, 1998–2002.
Risk factor HR (95% CI) P Adjusted HR (95% CI) P
Age (years) 0.008 0.003
18–30 2.1 (1.3–3.5) 2.4 (1.4–4.0)
31–40 1.7 (1.1–2.8) 1.6 (1.0–2.6)
41–50 1.3 (.81–2.2) 1.3 (0.8–2.2)
51–64 1.0 1.0
History of STI
No 1.0
Yes 1.6 (1.0–2.4) 0.03 -
Sexual behavior
No. of male sex partners in the last 6 months ,.0001 ,.0001
#4 1.0 1.0
5–10 2.2 (1.6–3.0) 1.8 (1.3–2.6)
.10 3.6 (2.7–4.9) 2.4 (1.7–3.3)
No HIV positive male sex partners 1.0 1.0
$1 HIV positive partner 2.1 (1.6–2.7) ,.0001 1.6 (1.2–2.0) .001
No UAI with an HIV positive/unknown partner 1.0 1.0
UAI with an HIV positive/unknown partner 2.9 (2.3–3.7) ,.0001 1.7 (1.3–2.3) ,.0001
Recreational drug use
No amphetamines 1.0 1.0
Amphetamines 2.9 (2.2–3.9) ,.0001 1.6 (1.1–2.1) .007
No tranquilizers 1.0
Tranquilizers 1.6 (1.2–2.2) 0.006 -
No hallucinogens 1.0
Hallucinogens 3.0 (2.7–3.3) ,.0001 -
No poppers 1.0 1.0
Poppers 2.7 (2.1–3.4) ,.0001 1.7 (1.3–2.2) ,.0001
No sexual performance enhancing drugs 1.0
Sexual performance enhancing drugs 2.0 (1.5–2.6) ,.0001 -
No cocaine 1.0
Cocaine 1.7 (1.2–2.3) 0.002 -
NOTE. Multivariate model controlled for race, treatment arm assignment, date of study entry, education level, and geographic region. CI, confidence interval; HR,
hazards ratio; UAI, unprotected anal intercourse.
doi:10.1371/journal.pone.0034972.t002
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continue to remain elevated among young MSM.
This analysis had several limitations. The study sample,
although regionally diverse, was not representative of MSM at
the state or national level and was not a population-based cohort.
Generalizability is limited since minority men, younger men, and
less educated men, made up smaller components of the study
population, and were also less likely to be retained in follow-up.
The study population also reflects only MSM interested in
participating in an HIV vaccine trial. Study eligibility criteria
were based on vaccine preparedness studies designed to enroll a
high-risk HIV-negative MSM population sufficiently powered to
detect a vaccine efficacy against sexual transmission and excluded
men with a history of IDU or in monogamous relationships with
HIV-negative men. Behavioral data were collected via an
interviewer-administered questionnaire, thus socially undesirable
drug using and sexual behaviors may have been underreported.
Lastly, the lack of data regarding frequency, type, and circum-
stances of recreational drug use or the presence of primary or
casual partners prevented in depth analysis of their contribution to
seroconversion.
MSM have been a population long-affected by HIV and
targeted for interventions by numerous prevention programs.
However, despite awareness of their risk for HIV infection, HIV
seroincidence continues to be elevated nationally among this
group, especially among young men [1,2,4,5,14]. Although unsafe
sexual risk behaviors were important predictors of HIV serocon-
version and should be highlighted in any MSM prevention
activity, our data and that of others reveal that drug use, in
particular amphetamines and poppers, are also strongly associated
with HIV infection. Most HIV risk reduction strategies concen-
trate largely on reducing sexual risk by encouraging condom use,
reducing the number of sexual partners, promoting safer sexual
practices, and stopping injection drug use [51]. Alcohol and other
substance use which may be addressed in the overall safer sex
guidelines may not be stressed as specific risk factors. The
consistent drug use over the course of the study in the face of
declining sexual risk behaviors [24] suggests that prevention
messages delivered in the HIV counseling and testing of MSM
may not adequately acknowledge or address all risk behaviors that
place them at risk for HIV infection. Continuing development of
promising new HIV prevention strategies [52,53] and intensifica-
tion of existing effective interventions (e.g. frequent repeat HIV
testing and early linkage to care and treatment [54–56]) will be
necessary to reduce the rate of HIV, especially among drug using
young MSM.
Acknowledgments
We thank the VAX004 study participants for their contributions to the
study, and the study staff for their contributions and implementation of the
trial. In addition, we thank the following individuals for their assistance
with data interpretation, graphics, and review and comments on the
manuscript: Gary Marks, Allen Hightower, and Eleanor McLellan.
Data were partially presented at the 11th Conference on Retroviruses
and Opportunistic Infections, February 8–11, 2004, San Francisco, CA.
Abstract 857.
Written informed consent was obtained from participants, and human
experimentation guidelines of the US Department of Health and Human
Services, and in accordance with the principles expressed in the
Declaration of Helsinki, were followed in the conduct of this research.
The finding and conclusions in this report are those of the authors and
do not necessarily represent the official position of the Centers for Disease
Control and Prevention.
Author Contributions
Conceived and designed the experiments: MA AEG BB MG. Performed
the experiments: AG ML MG. Analyzed the data: MA AEG CL BB.
Contributed reagents/materials/analysis tools: MA AEG CL BB AHG ML
MG. Wrote the paper: MA AEG CL BB AHG ML MG.
References
1. Prejean J, Song R, Hernandez A, Ziebell R, Green T, et al. (2011) Estimated
HIV Incidence in the United States, 2006–2009. PLoS One 6(8): e17502.
2. CDC (2001) Diagnoses of HIV infection and AIDS in the United States and
dependent areas, 2009, HIV Surveillance Report, Vol 21. Available:http://
www.cdc.gov/hiv/surveillance/resources/reports/2009report/index.htm via
the Internet. Accessed 15 March 2012.
3. Hall HI, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV
Incidence in the United States. JAMA 300(5): 520–529.
4. Valleroy LA, MacKellar DA, Karon JM, Rosen DH, McFarland W, et al. (2000)
HIV prevalence and associated risks in young men who have sex with men.
Young Men’s Survey Study Group. JAMA 284(2): 198–204.
5. Koblin BA, Torian LV, Guilin V, Ren L, MacKellar DA, et al. (2000) High
prevalence of HIV infection among young men who have sex with men in New
York City. AIDS 14(12): 1793–1800.
6. Chen SY, Gibson S, Katz MH, Klausner JD, Dilley JW, et al. (2002) Continuing
increases in sexual risk behavior and sexually transmitted diseases among men
who have sex with men: San Francisco, Calif, 1999–2001, USA. Am J Public
Health 92(9): 1387–1388.
7. Catania JA, Osmond D, Stall RD, Pollack L, Paul JP, et al. (2001) The
continuing HIV epidemic among men who have sex with men. Am J Public
Health 91(6): 907–914.
8. CDC (2003) Primary and secondary syphilis–United States, 2002. MMWR
52(46): 1117–1120.
9. CDC (2001) Outbreak of syphilis among men who have sex with men–Southern
California, 2000. MMWR 50(7): 117–120.
10. CDC (2002) Primary and secondary syphilis among men who have sex with
men–New York City, 2001. MMWR 51(38): 853–856.
11. Ekstrand ML, Stall RD, Paul JP, Osmond DH, Coates TJ (1999) Gay men
report high rates of unprotected anal sex with partners of unknown or discordant
HIV status. AIDS 13(12): 1525–1533.
12. Sullivan PS, Hamouda O, Delpech V, Geduld JE, Prejean J, et al. (2009)
Reemergence of the HIV Epidemic Among Men Who Have Sex With Men in
North America, Western Europe, and Australia, 1996–2005. Annals of
Epidemiology 19(6): 423–431.
13. CDC (2005) HIV prevalence, unrecognized infection, and HIV testing among
men who have sex with men–five U.S. cities, June 2004–April 2005. MMWR
54(24): 597–601.
14. CDC (2010) Prevalence and awareness of HIV infection among men who have
sex with men — 21 cities, United States, 2008. MMWR 59(37): 1201–7.
15. Buchacz K, Klausner JD, Kerndt PR, Shouse RL, Onorato I, et al. (2008) HIV
incidence among men diagnosed with early syphilis in Atlanta, San Francisco,
and Los Angeles, 2004 to 2005. J Acquir Immune Defic Syndr 1;47(2): 234–40.
16. Cohen J (2003) Clinical research. A setback and an advance on the AIDS
vaccine front. Science 300(5616): 28–29.
17. The rgp120 HIV vaccine study group (2005) Placebo-controlled phase 3 trial of
a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis
191(5): 654–665.
18. Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, et al. (2004)
Recruitment and baseline epidemiologic profile of participants in the first phase
3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 37(3): 1385–1392.
19. Buchbinder SP, Douglas JM, Jr., McKirnan DJ, Judson FN, Katz MH, et al.
(1996) Feasibility of human immunodeficiency virus vaccine trials in homosexual
men in the United States: risk behavior, seroincidence, and willingness to
participate. J Infect Dis 174: 954–961.
20. Seage GR, III, Holte SE, Metzger D, Koblin BA, Gross M, et al. (2001) Are US
populations appropriate for trials of human immunodeficiency virus vaccine?
The HIVNET Vaccine Preparedness Study. Am J Epidemiol 153(7): 619–627.
21. Koblin B, Chesney M, Coates T (2004) Effects of a behavioural intervention to
reduce acquisition of HIV infection among men who have sex with men: the
EXPLORE randomised controlled study. Lancet 364(9428): 41–50.
22. Fernyak SE, Page-Shafer K, Kellogg TA, McFarland W, Katz MH (2002) Risk
behaviors and HIV incidence among repeat testers at publicly funded HIV
testing sites in San Francisco. J Acquir Immune Defic Syndr 31(1): 63–70.
23. Page-Shafer K, Veugelers PJ, Moss AR, Strathdee S, Kaldor JM, et al. (1997)
Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual
men participating in the Tricontinental Seroconverter Study, 1982–1994.
Am J Epidemiol 146(7): 531–542.
HIV Seroincidence in US Men Who Have Sex with Men
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e3497224. Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, et al. (2005) HIV
Sexual Risk Behavior Over 36 Months of Follow-Up in the World’s First HIV
Vaccine Efficacy Trial. J Acquir Immune Defic Syndr 39(1): 90–101.
25. Weber AE, Craib KJ, Chan K, Martindale S, Miller ML, et al. (2003)
Determinants of HIV serconversion in an era of increasing HIV infection among
young gay and bisexual men. AIDS 17(5): 774–777.
26. Colfax G, Coates TJ, Husnik MJ, Huang Y, Buchbinder S, et al. (2005)
Longitudinal Patterns of Methamphetamine, Popper (Amyl Nitrite), and
Cocaine Use and High-Risk Sexual Behavior Among a Cohort of San Francisco
Men Who Have Sex with Men. J Urban Health 82(1 Suppl 1): i62–70.
27. Golden MR, Brewer DD, Kurth A, Holmes KK, Handsfield HH (2004)
Importance of Sex Partner HIV Status in HIV Risk Assessment Among Men
Who have Sex With Men. J Acquir Immune Defic Syndr 36(2): 734–742.
28. Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, et al. (2006) Risk
factors for HIV infection among men who have sex with men. AIDS 20(5):
731–739.
29. Mansergh G, Shouse RL, Marks G, Guzman R, Rader M, et al. (2006)
Methamphetamine and sildenafil (Viagra) use are linked to unprotected
receptive and insertive anal sex, respectively, in a sample of men who have
sex with men. Sex Transm Infect 82(2): 131–134.
30. Clatts MC, Goldsamt LA, Yi H (2005) Drug and Sexual Risk in Four Men Who
Have Sex with Men Populations: Evidence for a Sustained HIV Epidemic in
New York City. J Urban Health 82(1 Suppl 1): i9–17.
31. Colfax GN, Mansergh G, Guzman R, Vittinghoff E, Marks G, et al. (2001) Drug
use and sexual risk behavior among gay and bisexual men who attend circuit
parties: a venue-based comparison. J Acquir Immune Defic Syndr 28(4):
373–379.
32. Woody GE, Donnell D, Seage GR, Metzger D, Marmor M, et al. (1999) Non-
injection substance use correlates with risky sex among men having sex with
men: data from HIVNET. Drug Alcohol Depend 53(3): 197–205.
33. McNall M, Remafedi G (1999) Relationship of amphetamine and other
substance use to unprotected intercourse among young men who have sex with
men. Arch Pediatr Adolesc Med 153(11): 1130–1135.
34. Rusch M, Lampinen TM, Schilder A, Hogg RS (2004) Unprotected anal
intercourse associated with recreational drug use among young men who have
sex with men depends on partner type and intercourse role. Sex Transm Dis
31(8): 492–498.
35. Fernandez MI, Perrino T, Collazo JB, Varga LM, Marsh D, et al. (2005) Surfing
New Territory: Club-Drug Use and Risky Sex Among Hispanic Men Who Have
Sex with Men Recruited on the Internet. J Urban Health 82(1 Suppl 1): i79–88.
36. Hirshfield S, Remien RH, Humberstone M, Walavalkar I, Chiasson MA (2004)
Substance use and high-risk sex among men who have sex with men: a national
online study in the USA. AIDS Care 16(8): 1036–1047.
37. Stone E, Heagerty P, Vittinghoff E, Douglas JM, Jr., Koblin BA, et al. (1999)
Correlates of condom failure in a sexually active cohort of men who have sex
with men. J Acquir Immune Defic Syndr Hum Retrovirol 20(5): 495–501.
38. Burcham JL, Tindall B, Marmor M, Cooper DA, Berry G, et al. (1989)
Incidence and risk factors for human immunodeficiency virus seroconversion in
a cohort of Sydney homosexual men. Med J Aust 150(11): 634–639.
39. Weinstock H, Sweeney S, Satten GA, Gwinn M (1998) HIV seroincidence and
risk factors among patients repeatedly tested for HIV attending sexually
transmitted disease clinics in the United States, 1991 to 1996. STD Clinic HIV
Seroincidence Study Group. J Acquir Immune Defic Syndr Hum Retrovirol
19(5): 506–512.
40. Holmberg SD (1996) The estimated prevalence and incidence of HIV in 96
large US metropolitan areas. Am J Public Health 86(5): 642–654.
41. CDC (2001) HIV incidence among young men who have sex with men–seven
U.S. cities, 1994–2000. MMWR 50(21): 440–444.
42. Mansergh G, Marks G (1998) Age and risk of HIV infection in men who have
sex with men. AIDS 12(10): 1119–1128.
43. Morris M, Zavisca J, Dean L (1995) Social and sexual networks: their role in the
spread of HIV/AIDS among young gay men. AIDS Educ Prev 7(5 Suppl):
24–35.
44. Crepaz N, Marks G, Mansergh G, Murphy S, Miller LC, et al. (2000) Age-
related risk for HIV infection in men who have sex with men: examination of
behavioral, relationship, and serostatus variables. AIDS Educ Prev 12(5):
405–415.
45. Benotsch EG, Kalichman S, Cage M (2002) Men who have met sex partners via
the Internet: prevalence, predictors, and implications for HIV prevention. Arch
Sex Behav 31(2): 177–183.
46. Kim AA, Kent C, McFarland W, Klausner JD (2001) Cruising on the Internet
highway. J Acquir Immune Defic Syndr 28(1): 89–93.
47. Rietmeijer CA, Bull SS, McFarlane M, Patnaik JL, Douglas JM, Jr. (2003) Risks
and benefits of the internet for populations at risk for sexually transmitted
infections (STIs): results of an STI clinic survey. Sex Transm Dis 30(1): 15–19.
48. McFarlane M, Bull SS, Rietmeijer CA (2000) The Internet as a newly emerging
risk environment for sexually transmitted diseases. JAMA 284(4): 443–446.
49. Garofalo R, Herrick A, Mustanski BS, Donenberg GR (2007) Tip of the Iceberg:
young men who have sex with men, the Internet, and HIV risk. Am J Public
Health 97(6): 1113–7.
50. Flores SA, Mansergh G, Marks G, Guzman R, Colfax G (2009) Gay identity-
related factors and sexual risk among men who have sex with men in San
Francisco. AIDS Educ Prev 21(2): 91–103.
51. CDC (2001) Revised Guidelines for HIV Counseling and Testing. MMWR
Recomm Rep 50(RR19): 1–58.
52. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010)
Preexposure chemoprophylaxis for HIV prevention in men who have sex with
men. N Engl J Med 363(27): 2587–99.
53. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011)
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med
365(6): 493–505.
54. Workowski KA, Berman S, CDC (2010) Sexually Transmitted Diseases
Treatment Guidelines, 2010. MMWR Recomm Rep 59(RR-12): 1–110.
55. Metsch LR, Pereyra M, Messinger S, Del Rio C, Strathdee SA, et al. (2008) HIV
transmission risk behaviors among HIV-infected persons who are successfully
linked to care. Clin Infect Dis 47(4): 577–84.
56. CDC (2011) HIV Testing Among Men Who Have Sex with Men — 21 Cities,
United States, 2008. MMWR 60(21): 694–699.
HIV Seroincidence in US Men Who Have Sex with Men
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34972